Listed Tyneside pharmaceutical firm Shield Therapeutics has appointed a new CEO. The Gateshead drug discovery business, which ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a ...

Secretary of State for Science, Innovation and Technology Rt Hon Peter Kyle and Minister of State for Science, Research and ...

Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The findings suggest that "supportive care and management of geriatric vulnerabilities at baseline may improve outcomes and ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Competition is already heating up, with many companies taking a unique approach to developing their quantum computers. One ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

When Oxford University developed the AstraZeneca vaccine, Dr Sue Pavord, a consultant haematologist, was so eager for it to ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...